ArticleJournal of cellular and molecular medicine2026
HBx Promotes Liver Cancer Cells to Escape NK-92 Cell Attack by Mediating ADAM10 to Enzyme Cut MICA/B Shedding From Cancer Cell Membrane.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the MICA/B-NKG2D axis in cancer: from molecular structure to immunotherapeutic strategies-a narrative review.Translational cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
MICA/B shedding from the membrane of cancer cells can inhibit natural killer (NK) cells from attacking hepatocellular carcinoma (HCC). This study explored the role of HBx in mediating MICA/B shedding. The expression of HBx, MICA/B and HIF-1α in HBV-infected HCC was analysed using bioinformatics, and the localization of these proteins in tissues was verified using immunohistochemistry and immunofluorescence. HBx-related signalling pathways were screened using RNA sequencing and KEGG pathway enrichment analyses. The expression of ADAM10 and MICA/B was detected by Western blotting, and the dynamic changes of MICA/B in the membrane and supernatant were evaluated by flow cytometry and ELISA. The HIF-1α inhibitor (LW-6) and ADAM10 inhibitor (GI254023X) were used to treat the HCC cells. The killing effect of NK-92 cells on HCC cells was evaluated using lactate dehydrogenase release, cytotoxicity assays, clone formation and live-cell imaging, and the secretion levels of IFN-γ, IL-2 and IL-10 were measured. These results indicated that HBx, MICA/B and HIF-1α were highly expressed in HBV-infected HCC tissues. HBx promotes shedding of MICA/B from HCC cell membranes by upregulating the activity of ADAM10. LW-6 reversed the induction effect of HBx on ADAM10 and GI254023X significantly restored MICA/B levels on the membrane surface of HCC cells. Overexpression of HBx increases the resistance of HCC cells to NK-92 cells and inhibits the secretion of IFN-γ, IL-2 and IL-10. In conclusion, HBx regulates the expression of ADAM10 by activating the HIF-1α signalling pathway. ADAM10 cuts MICA/B shedding from the membrane surface of HCC cells, resulting in escape attack by NK-92 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.